Electrophysiologic effects and clinical efficacy of flecainide in children with recurrent paroxysmal supraventricular tachycardia

Musto, B; D’Onofrio, Antonio; Cavallaro, Giro; Musto, Antonio; Greco, R.

doi:10.1016/0002-9149(88)90217-2

Cited by 21 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Die Dosis der beiden letztgenannten Arbeiten lag bei 300-380 mg/m 2 KO Tag aufgeteilt in 3 Dosen und erreichte in 80% der Fälle einen kompletten Erfolg. Flecainid verlängert die antegrade Leitung des akzessorischen Bündels und blockiert die retrograde Leitung [29]. Hierbei werden Erfolgsraten zwischen 7 und 85% angegeben [42,50,60].…”

Section: Das Klasse-ic-antiarrhythmikumunclassified

Wolff-Parkinson-White-Syndrom

Loeff¹,

Reithmann²,

Hoffmann³

et al. 2001

Monatsschrift Kinderheilkunde

View full text Add to dashboard Cite

Section: Das Klasse-ic-antiarrhythmikumunclassified

Wolff-Parkinson-White-Syndrom

Loeff¹,

Reithmann²,

Hoffmann³

et al. 2001

Monatsschrift Kinderheilkunde

View full text Add to dashboard Cite

“…Flecainide acetate has been used successfully in the management of resistant childhood dysrhythmias, particularly SVT, but also VT (2,3,4). It significantly prolongs accessory pathway refractoriness yet has little effect on the refractoriness of normal cardiac muscle (5,6).…”

Section: Ventricular Tachycardia Is Rare In Children (1) Unlike In Amentioning

confidence: 99%

Ventricular Tachycardia Associated with Coxsackie B4 Virus Infection

Tubman¹,

Craig²,

Mulholland³

1990

Acta Paediatrica

View full text Add to dashboard Cite

show abstract

“…Whether the results of the CAST study can be extrapolated to other patient groups is unknown. The antiarrhythmic ef fects of flecainide in paroxysmal supraven tricular tachycardias associated with the WolfT-Parkinson-White syndrome or with dual AV nodal pathways are well docu mented [7][8][9].…”

mentioning

confidence: 99%

Clinical Efficacy of Flecainide Acetate in Atrial Fibrillation

Mary-Rabine

Kulbertus²

1990

Cardiology

View full text Add to dashboard Cite

Seventy-seven patients with symptomatic atrial fibrillation (AF) received oral flecainide acetate (247 ± 8 mg/day). In 66 patients, previous antiarrhythmic trials consisted of 1–9 drugs. In 55 cases, AF was paroxysmal. It was persistent in 22 patients. Conversion and/or no recurrence of AF was achieved in 40 patients (52%) by flecainide alone and in 11 (14%) by the combination of flecainide and amiodarone. The mean flecainide serum level was 535 ± 46 ng/ml. Age, presence of coronary artery disease or electrocardiographic parameters were not useful for predicting clinical response. In persistent AF, flecainide efficacy decreased with the duration of arrhythmia. Side effects concerned conduction (26%) and congestive heart failure (5%).

show abstract

Electrophysiologic effects and clinical efficacy of flecainide in children with recurrent paroxysmal supraventricular tachycardia

Cited by 21 publications

References 10 publications

Wolff-Parkinson-White-Syndrom

Wolff-Parkinson-White-Syndrom

Ventricular Tachycardia Associated with Coxsackie B4 Virus Infection

Clinical Efficacy of Flecainide Acetate in Atrial Fibrillation

Contact Info

Product

Resources

About